Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025)
Immutep (IMMP) posted Net Income towards Common Stockholders of $64.9 million for Q4 2025, down 29.41% on a QoQ basis from $92.0 million in Q2 2025, and down 42.43% year-over-year from $112.8 million in Q4 2024.
Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends
Immutep's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at $64.9 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 42.43% year-over-year to $64.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $394.6 million (down 2.37% YoY) and the FY2025 annual result came in at $92.0 million, down 26.35% from the prior year.
- Net Income towards Common Stockholders was $64.9 million for Q4 2025 at Immutep, down from $92.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $124.9 million in Q2 2024 and bottomed at $50.4 million in Q4 2022.
- A 5-year average of $81.5 million and a median of $77.3 million in 2021 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders jumped 158.52% — and 2025, when it slumped 42.43%.
- Immutep's Net Income towards Common Stockholders stood at $79.3 million in 2021, then sank by 36.48% to $50.4 million in 2022, then soared by 49.41% to $75.3 million in 2023, then jumped by 49.82% to $112.8 million in 2024, then slumped by 42.43% to $64.9 million in 2025.
- Business Quant data shows IMMP's Net Income towards Common Stockholders at $64.9 million in Q4 2025, $92.0 million in Q2 2025, and $112.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | -0.68 |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immutep | 559.62 Mn | 559.62 Mn | - | 64.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.93 Mn |
| Jun 30, 2025 | 91.99 Mn |
| Dec 31, 2024 | 112.79 Mn |
| Jun 30, 2024 | 124.90 Mn |
| Dec 31, 2023 | 75.28 Mn |
| Jun 30, 2023 | 91.21 Mn |
| Dec 31, 2022 | 50.39 Mn |
| Jun 30, 2022 | 67.38 Mn |
| Dec 31, 2021 | 79.32 Mn |
| Jun 30, 2021 | 56.42 Mn |
| Dec 31, 2020 | 44.36 Mn |
| Jun 30, 2020 | 21.83 Mn |
| Dec 31, 2019 | 19.15 Mn |
| Jun 30, 2019 | 17.08 Mn |
| Dec 31, 2018 | 24.05 Mn |
| Jun 30, 2018 | 25.38 Mn |
| Jun 30, 2017 | -2.31 Mn |
| Mar 31, 2017 | -1.69 Mn |
| Dec 31, 2016 | -3.10 Mn |
| Jun 30, 2016 | -2.63 Mn |